SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced favorable preclinical results ...

Approved JAK inhibitors such as ruxolitinib and fedratinib target the JH1 kinase domain, offering symptomatic relief but lacking selectivity for the mutant form. This non-selective inhibition disrupts ...

Wyoming High School is following a statewide trend of high schools offering more AP classes, and more students taking them.

What you wear on a plane reveals your background, sure. But more importantly, it reveals that all of us are carrying ...

Democratic Socialism’s rise portends “nothing good,” because “this version [of leftism] is even dumber” than its predecessors ...

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Updated data from RUBY-3 ...

Learn about Schlafly Brewery with brewery class in Edwardsville ...

Nine individuals who contributed to the sport of professional football in distinct ways have reached the Semifinalists stage ...

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody - Phase 1 dose escalation study in Immune ...

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the Phase 3 VERIFY study, will be the focus of four ...

Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune diseases and cancer, today announced its management team ...